Koers GENB AS Other OTC
Aandelen
US3723032062
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 19,8 mld. 2,88 mld. 2,65 mld. | Omzet 2025 * | 23,62 mld. 3,43 mld. 3,16 mld. | Marktkapitalisatie | 125 mld. 18,17 mld. 16,73 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 4,67 mld. 679 mln. 626 mln. | Nettowinst (verlies) 2025 * | 6,61 mld. 962 mln. 886 mln. | EV/omzet 2024 * | 5 x |
Nettoliquiditeiten 2024 * | 25,9 mld. 3,77 mld. 3,47 mld. | Nettoliquiditeiten 2025 * | 32,35 mld. 4,7 mld. 4,33 mld. | EV/omzet 2025 * | 3,92 x |
K/w-verhouding 2024 * |
28,5
x | K/w-verhouding 2025 * |
20,5
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,51% |
Recentste transcriptie over GENB AS
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 63 | 01-01-99 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 01-01-07 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 23-03-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 01-01-17 |
Director/Board Member | 73 | 01-11-03 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 01-01-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+11,91% | 118 mld. | |
+11,60% | 106 mld. | |
-4,68% | 24,28 mld. | |
-0,82% | 21,96 mld. | |
-42,12% | 16,37 mld. | |
-17,47% | 15,56 mld. | |
+2,77% | 13,63 mld. | |
+34,58% | 12,27 mld. | |
+77,64% | 8,87 mld. |